Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053482 · ClinicalTrials.gov registry record · Phase 2
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
A Phase 2 study, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 357
- Enrollment target
NCT00053482 is a Phase 2 study that has completed, run by Emergent BioSolutions. The registered enrollment target is 357 participants.
The verdict
NCT00053482, a Phase 2 study, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 357 participants
- Enrollment target
Study Summary
The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
Interventions
- BIOLOGICAL ACAM2000 Smallpox Vaccine
- BIOLOGICAL Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053482
The ClinicalTrials.gov registry entry for NCT00053482 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ACAM2000 Smallpox Vaccine is the first listed.
NCT00053482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053482 about?
NCT00053482 is a clinical study titled "Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults". The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
What is the current status of trial NCT00053482?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2003-01. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00053482?
The interventions under investigation include: ACAM2000 Smallpox Vaccine (BIOLOGICAL), Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00053482?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.